Forlong Biotechnology has dosed the first patient in an Australian Phase 1 clinical trial of subcutaneous FL115, an investigational interleukin-15 superagonist being developed for patients with advanced solid tumours. Announced on October 26, 2026, the development marks the first clinical evaluation of the subcutaneous formulation, which is designed to maintain immune stimulation while reducing the high peak blood concentrations associated with intravenous administration.
The programme builds on earlier clinical investigations of intravenous FL115, in which Forlong Biotechnology reported expansion of natural killer cells and T cells alongside preliminary antitumour activity in selected patients. The new formulation is supported by preclinical findings showing more than a 20-fold reduction in maximum plasma concentration compared with intravenous delivery, together with prolonged systemic exposure and bioavailability of at least 60%. These findings provide a rationale for clinical investigation but do not establish that the subcutaneous product will be safer or more effective in humans.
The Australian study follows regulatory and ethics processes completed earlier in 2026, allowing the company to investigate FL115 through a subcutaneous dosing schedule. Its initial objectives will centre on safety, tolerability and the relationship between dose, exposure and biological activity. The first-patient dosing milestone confirms that clinical testing has begun, rather than demonstrating a therapeutic effect.
Why is subcutaneous administration becoming an important development strategy for Forlong Biotechnology’s FL115 programme?
Interleukin-15 is a cytokine involved in regulating immune cells that can recognise and attack abnormal cells, including some cancer cells. Its biological activity has attracted considerable interest in oncology because it can stimulate natural killer cells and CD8-positive T cells. However, achieving sustained immune activation without unacceptable systemic toxicity has been a major challenge for cytokine-based treatment development.
Intravenous administration introduces a drug directly into the circulation, potentially producing relatively high concentrations soon after dosing. These peak levels may influence the intensity and timing of immune stimulation, particularly with treatments that activate multiple immune-cell populations. For cytokine therapies, excessive or poorly controlled immune activation can complicate the relationship between drug exposure and tolerability.
Subcutaneous administration offers a different absorption profile because the medicine enters the circulation gradually from tissue beneath the skin. Depending on the molecule and formulation, this can reduce peak concentrations and prolong exposure. However, the extent of any advantage must be determined experimentally rather than assumed from the route of administration alone.
Forlong Biotechnology is investigating whether these pharmacokinetic characteristics can improve the therapeutic window of FL115. The intended objective is to maintain sufficient immune stimulation for antitumour activity while avoiding unnecessarily high systemic exposure. The company has not yet disclosed human pharmacokinetic results for the subcutaneous formulation.
The Australian trial therefore represents a formulation-development strategy as well as an expansion of the clinical programme. Its importance lies in testing whether changing the administration route modifies FL115’s biological and safety characteristics in a clinically useful manner.
How does FL115 stimulate natural killer cells and T cells through its engineered IL-15 mechanism?
FL115 is an engineered fusion protein combining interleukin-15, an interleukin-15 receptor alpha component and Forlong Biotechnology’s proprietary Fbody technology. The design is intended to support sustained biological activity while reducing certain structural complexities associated with conventional Fc-based fusion proteins. Its principal therapeutic objective is to stimulate immune-cell populations involved in recognising and eliminating malignant cells.
Interleukin-15 signalling plays an important role in the development, survival and activity of natural killer cells. These cells form part of the innate immune system and can recognise some abnormal or stressed cells without requiring the same antigen-specific activation processes used by conventional T cells. Increasing their number or activity is one strategy being investigated to strengthen antitumour immunity.
The cytokine also supports CD8-positive T cells, which can directly recognise and destroy cells displaying appropriate antigenic targets. These cells are central to several established and experimental cancer immunotherapies. However, increasing immune-cell numbers does not automatically produce effective tumour elimination, particularly when cancers employ mechanisms that suppress immune activity.
Forlong Biotechnology has reported that intravenous FL115 produces substantial expansion of natural killer cells and T cells in early clinical investigations. The company also observed induction of interferon gamma, a cytokine associated with immune activation. These pharmacodynamic findings support the intended mechanism, although they are not equivalent to evidence of durable tumour response.
The subcutaneous programme will need to establish whether gradual systemic absorption preserves these immune effects. Researchers will also need to examine whether the magnitude and timing of immune stimulation differ meaningfully from intravenous administration. The resulting balance between biological activity and toxicity will influence future dose selection.
What do the preclinical pharmacokinetic findings reveal about the potential advantages of subcutaneous FL115?
Forlong Biotechnology reported that subcutaneous administration reduced the maximum plasma concentration of FL115 by more than 20-fold compared with intravenous administration in preclinical studies. The company also observed prolonged meaningful systemic exposure, suggesting that the lower peak concentration did not simply reflect rapid elimination or complete failure of absorption. This combination provides a biological rationale for evaluating a less concentrated exposure profile.
Preclinical systemic bioavailability was reported at 60% or greater. This indicates that a substantial proportion of the administered drug reached the circulation under the experimental conditions. However, bioavailability measurements do not establish how much of the medicine reaches a particular tumour or whether the exposure is sufficient for clinical activity.
The company also reported no significant gross skin irritation in the evaluated preclinical models. This observation is relevant because subcutaneous cytokine administration can cause local reactions, including discomfort, inflammation and swelling. Nevertheless, laboratory observations cannot exclude injection-site complications in patients receiving repeated treatment.
A lower maximum concentration could potentially affect tolerability if certain adverse effects are related to peak exposure. However, some cytokine-associated toxicities may depend on cumulative exposure, immune-cell activation or biological factors not captured by a single pharmacokinetic measurement. Lower peak concentrations therefore do not establish that systemic inflammatory reactions will be reduced in humans.
The prolonged exposure profile may also create a trade-off. Sustained immune stimulation could support the intended therapeutic mechanism, but longer exposure might increase the duration of certain adverse effects. The Australian study will need to evaluate both possibilities before the formulation can be considered clinically differentiated.
What did earlier intravenous FL115 studies demonstrate about antitumour activity and treatment durability?
The subcutaneous programme follows two completed Phase 1 investigations of intravenous FL115 monotherapy in patients with advanced solid tumours. Forlong Biotechnology reported in May 2026 that these studies had been conducted in the United States and China, treating 11 and 23 patients, respectively. The combined experience provides preliminary human safety and pharmacodynamic information for the active molecule.
In the US FL115-101 study, one patient with advanced cervical cancer achieved stable disease after receiving the investigational treatment. The patient had previously undergone four lines of therapy and subsequently continued receiving FL115 through an individual investigational treatment arrangement after the original study ended. The duration of disease control extended beyond 12 months according to the company’s disclosures.
In the Chinese FL115-102 study, two patients achieved confirmed partial responses. One had a highly aggressive form of non-small-cell lung cancer associated with NUT alterations, while the other had lymphoepithelial carcinoma involving the parotid gland. Both had received multiple previous treatments, and Forlong Biotechnology reported continued access to FL115 through compassionate treatment arrangements after their study participation ended.
These observations provide evidence of preliminary antitumour activity in selected heavily pretreated patients. However, two confirmed partial responses and one prolonged period of stable disease across the reported early clinical programme do not establish a reliable response rate for the broader population of patients with advanced solid tumours. The studies were early-phase investigations without randomised control groups.
The distinction between stable disease and partial response is also important. Stable disease indicates that tumour measurements did not meet specified criteria for progression or response during the assessed period, whereas a confirmed partial response requires a defined reduction in measurable tumour burden. Their clinical significance depends on baseline disease behaviour, treatment duration and other patient characteristics.
The earlier findings justify further investigation of FL115 but should not be interpreted as evidence that the subcutaneous formulation will reproduce the same outcomes. The new route of administration could alter exposure, biological activity and tolerability, requiring its own clinical assessment.
Why will cytokine-related safety and inflammatory responses be central to the Australian Phase 1 trial?
The safety of immune-stimulating cytokines is an important development consideration because their biological effects can extend across several immune-cell populations. Excessive cytokine activity may produce fever, fatigue, blood pressure changes and other systemic reactions. The nature and severity of these effects depend on the specific molecule, dose and characteristics of the treated patient.
Forlong Biotechnology has reported that intravenous FL115 stimulates interferon gamma while producing relatively limited systemic interleukin-6 induction at lower doses. This is relevant because interleukin-6 is associated with inflammatory processes involved in some cytokine-related toxicities. However, the absence of marked interleukin-6 increases under selected conditions does not establish that the treatment cannot produce serious inflammatory complications.
The Australian Phase 1 trial will need to examine adverse events alongside pharmacokinetic and pharmacodynamic measurements. Investigators will assess how the medicine behaves after subcutaneous administration and whether dose increases produce unexpected toxicity. Laboratory monitoring and clinical observations will be important for characterising the treatment’s biological effects.
Injection-site tolerability will represent another component of the assessment. Local reactions may affect patient comfort and the practicality of repeated administration even when systemic exposure is acceptable. The frequency and severity of such reactions cannot be determined from preclinical observations alone.
Longer-term tolerability will also matter if FL115 is eventually developed for repeated administration. A regimen that appears manageable after an initial dose may produce different effects over several treatment cycles. Continued evaluation will therefore be necessary to establish a suitable balance between exposure, immune stimulation and patient safety.
How will the Australian trial evaluate FL115 after the company completed its initial regulatory preparations?
Forlong Biotechnology announced in August 2026 that the subcutaneous FL115 study had received the necessary ethics approval and proceeded under Australia’s Therapeutic Goods Administration Clinical Trial Notification scheme. The proposed regimen involves administration once every three weeks in patients with advanced solid tumours. The October announcement confirms that the programme has progressed from preparation into patient dosing.
Australia’s Clinical Trial Notification framework allows eligible clinical investigations to proceed through the required sponsor and ethics processes, with notification to the Therapeutic Goods Administration. This should not be confused with marketing approval for the investigational medicine. FL115 remains an experimental treatment and is not authorised for routine commercial use.
The company has not disclosed the complete trial protocol in its October announcement. Patient enrolment targets, detailed dose-escalation rules, prespecified endpoints and the anticipated completion date were not provided. Consequently, the precise structure of the clinical assessment cannot be reconstructed from the announcement alone.
Nevertheless, the central development objectives are clear from the programme’s rationale. The study must establish whether subcutaneous administration produces an acceptable safety profile and whether the altered exposure pattern supports relevant immune-cell activity. Researchers will also be interested in any preliminary evidence of tumour response, although Phase 1 studies are generally not designed to provide definitive efficacy conclusions.
The next meaningful milestone will be a clinical update containing actual safety and pharmacokinetic results. Those findings will determine whether the preclinical reduction in peak exposure can be reproduced in patients and whether the company can identify a dosing regimen suitable for continued development.
How does the subcutaneous FL115 programme fit alongside Forlong Biotechnology’s bladder cancer development strategy?
Forlong Biotechnology is investigating FL115 through several administration routes and treatment combinations. In addition to the new subcutaneous study, the company is evaluating intravenous FL115 with an anti-PD-1 antibody in patients with advanced solid tumours. It is also developing intravesical FL115 in combination with Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
These approaches address different clinical and pharmacological objectives. Systemic administration aims to stimulate immune responses throughout the body, while intravesical delivery introduces treatment directly into the bladder. The local approach may provide a different relationship between treatment exposure and the targeted disease site.
Forlong Biotechnology has reported progress with the intravesical programme in patients with non-muscle-invasive bladder cancer. The company has been evaluating FL115 with Bacillus Calmette-Guérin in a Phase 2 study and is preparing for advancement into Phase 3 development. However, preparations for a pivotal trial do not establish that a Phase 3 study has begun or that the treatment has demonstrated confirmatory efficacy.
The company has also reported production of a pivotal clinical manufacturing batch intended to support its planned bladder cancer programme. This manufacturing milestone is relevant to future clinical supply but should not be confused with commercial-scale production or regulatory approval. Additional quality and regulatory requirements will apply as development progresses.
The different delivery strategies may allow Forlong Biotechnology to investigate FL115 across several oncology settings. However, results from one route of administration cannot automatically establish safety or efficacy for another. Each programme must generate evidence appropriate to its disease setting, combination regimen and intended clinical use.
Could combining FL115 with immune checkpoint inhibitors improve antitumour activity in advanced solid tumours?
Immune checkpoint inhibitors have become important treatments for several cancer types, but many patients do not respond or eventually experience disease progression. One reason is that tumours can develop mechanisms that limit effective immune-cell recognition and activity. Combining checkpoint blockade with treatments that stimulate immune-cell populations is therefore an active area of oncology research.
FL115’s biological activity provides a rationale for such combinations because interleukin-15 signalling can support natural killer cells and CD8-positive T cells. In principle, strengthening these populations could complement therapies that reduce inhibitory immune signalling. However, the relationship between increased immune-cell activity and tumour response is complex.
Forlong Biotechnology is investigating intravenous FL115 alongside an anti-PD-1 antibody in an early-phase clinical programme. The company has also reported preclinical antitumour activity involving FL115 combinations. These findings provide a research basis for continued development but do not establish that the combination is superior to checkpoint inhibition alone.
Safety presents another consideration because combining immune-stimulating treatments may alter the frequency or severity of inflammatory adverse events. The appropriate dose of FL115 when used with another immunotherapy may differ from the dose selected for monotherapy. Such questions require dedicated clinical investigation.
The subcutaneous formulation could eventually become relevant to combination development if it produces a favourable exposure and tolerability profile. However, no evidence currently establishes that subcutaneous FL115 improves checkpoint inhibitor outcomes. Its role in future combination regimens remains a development possibility rather than a demonstrated treatment advantage.
What does the FL115 expansion mean for Forlong Biotechnology’s financing and commercial development?
Forlong Biotechnology is a privately held biotechnology developer based in China, with research and clinical activities extending into international markets. The company has established several technology platforms, including its Fbody long-acting fusion technology and additional cytokine engineering capabilities. FL115 is its lead clinical asset and the principal focus of its current oncology development strategy.
The October announcement follows completion of a pre-Series B financing round, which management has identified as supporting acceleration of the company’s clinical programmes. However, the company did not disclose the amount raised or provide sufficient financial information to assess its remaining development runway. Its ability to support multiple studies will depend on the resources available and future financing requirements.
Dong Wei, chief executive officer of Forlong Biotechnology, has described the subcutaneous programme as part of a broader effort to optimise FL115’s therapeutic window and extend its potential applications. Management is also pursuing later-stage development in non-muscle-invasive bladder cancer while continuing systemic immunotherapy research. These activities create several potential development pathways but also introduce substantial operational demands.
Commercial prospects remain uncertain because FL115 has not received marketing approval for any indication. The company must demonstrate clinically meaningful efficacy, manageable safety and a viable manufacturing process before future revenue can be considered. Competition from other cytokine therapies and established cancer treatments will also influence eventual positioning.
The new Australian trial creates an opportunity to establish whether the formulation can improve the pharmacokinetic characteristics of FL115 in humans. If the lower peak exposure and prolonged drug availability observed in preclinical studies are reproduced clinically, the results could inform subsequent dose selection and combination strategies. The critical question is whether those pharmacological changes translate into a better balance between immune stimulation, tolerability and antitumour activity.
First-patient dosing therefore represents a genuine development milestone without establishing clinical success. Forlong Biotechnology has progressed from formulation research into human evaluation, supported by earlier intravenous experience and a broader oncology pipeline. The next decisive evidence will be the safety, pharmacokinetic and pharmacodynamic findings generated by the Australian Phase 1 study.
